文献速递神经免疫

COMBAT-MS:一项基于人群的观察性队列研究,比较多种多发性硬化疗法与利妥昔单抗的获益-风险平衡

COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab.
PubMed 文献 · Ann Neurol · 2024-06-25

该瑞典队列研究纳入复发缓解型多发性硬化患者,比较超说明书低剂量利妥昔单抗与获批疗法的有效性和安全性。利妥昔单抗组3年残疾进展比例与获批疗法无显著差异,复发率更低且治疗持续性更高,但转换治疗后住院感染率更高。

要点

  • 利妥昔单抗作为首次治疗或转换治疗,3年残疾进展比例与获批疗法无显著差异。
  • 利妥昔单抗组复发率更低、治疗持续性更高,但转换治疗后住院感染率更高。
  • 利妥昔单抗组残疾进展多独立于复发,MSIS-29评分变化与获批疗法大多相似。

核心结论

  • 这项基于人群的真实世界队列研究发现残疾进展率低,且多独立于复发,利妥昔单抗与获批疗法之间无显著差异;利妥昔单抗炎症活动率更低、治疗持续性更高,但与严重感染率增加相关。

研究设计与样本

  • 瑞典队列研究,纳入2011年至2018年间首次开始治疗或首次转换治疗的18至75岁复发缓解型多发性硬化患者。
  • 共纳入2449例作为首次治疗开始和2463例作为首次治疗转换,比较低剂量利妥昔单抗与获批多发性硬化疗法。
  • 采用意向性治疗分析,并校正人口学、多发性硬化特征和健康特征。

主要发现

  • 3年残疾进展比例:利妥昔单抗作为首次治疗为9.1%,转换治疗后为5.1%,与获批对照药物无差异。
  • 利妥昔单抗组残疾进展多独立于复发。
  • 3年MSIS-29评分(身体/心理)在利妥昔单抗首次疾病修饰治疗组改善1.3/8.4分,转换治疗组改善0.4/3.6分,各疗法间大多相似。
  • 利妥昔单抗在两组中复发率更低且治疗持续性更高。
  • 转换治疗后利妥昔单抗组住院治疗感染率更高,但作为首次治疗时未升高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess comparative effectiveness, safety, and tolerability of off-label rituximab, compared with frequently used therapies approved for multiple sclerosis (MS). METHODS: A Swedish cohort study of persons with relapsing-remitting MS, age 18 to 75 years at inclusion and with a first therapy start or a first therapy switch between 2011 and 2018. Low-dose rituximab was compared with MS-approved therapies. Primary outcomes were proportions with 12 months confirmed disability worsening and change in MS Impact Scale-29 (MSIS-29) scores, respectively. Secondary endpoints included relapses, therapy discontinuation, and serious adverse events. Analyses used an intention-to-treat approach and were adjusted for demographics, MS features, and health characteristics. RESULTS: We included 2,449 participants as first therapy start and 2,463 as first therapy switch. Proportions with disability worsening at 3 years were 9.1% for rituximab as first therapy and 5.1% after therapy switch, with no differences to MS-approved comparators. Worsening on rituximab was mostly independent of relapses. MSIS-29 with rituximab at 3 years improved by 1.3/8.4 points (physical/psychological) for first disease-modifying therapy (DMT) and 0.4/3.6 for DMT switch, and was mostly similar across therapies. Rituximab had lower relapse rates and higher therapy persistence in both groups. The rate of hospital-treated infections was higher with rituximab after a therapy switch, but not as a first therapy. INTERPRETATION: This population-based real-world cohort study found low rates of disability progression, mostly independent of relapses, and without significant differences between rituximab and MS-approved comparators. Rituximab led to lower rates of inflammatory activity and higher treatment persistence, but was associated with an increased rate of serious infections. ANN NEUROL 2024;96:678-693.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Piehl F, Alping P, Virtanen S, et al. COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab. Ann Neurol. 2024. PMID: 38923558. doi:10.1002/ana.27012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。